US regulators have, however, accepted the drug for review to treat hallucinations and delusions associated with dementia-related psychosis
News
AbbVie’s Rinvoq hits targets in atopic dermatitis trial
The JAK inhibitor significantly improved skin clearance and reduced itch
New data shows steep rise in people waiting for cancer tests
CR UK data also shows 2.3 million fewer tests have taken place compared to a year ago
Trainee GP numbers rise for third year running
GP trainee numbers in England have risen for the third year in a row, with recruitment up a record 15% versus last year
UCLB, Apollo secure first licensing deal with US investment powerhouse
Deerfield is partnering on the development of a novel gene therapy
UK launch for Ajovy injector pen
Teva’s new device allows migraine sufferers to self-administer the drug
Interim data shows strong responses to AZ/Oxford Uni’s COVID-19 vaccine
Researchers reported a four-fold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants
Janssen/MeiraGTx sight loss gene therapy hits targets
Interim six-month data of RPGR gene therapy shows significant vision improvement in patients with X-linked retinitis pigmentosa
GSK and CureVac form mRNA tech collaboration
GSK to make equity investment of £130m in CureVac as part of the deal
Synairgen’s SNG001 shows strong promise in COVID-19 trial
The drug significantly cut the risk of developing severe disease and patients were twice as likely to recover versus placebo
Gov signs deals with BioNTech/Pfizer and Valneva for COVID vaccines
The UK has now secured early access to three different types of promising COVID-19 vaccine candidates
AZ’ Farxiga fast-tracked for heart failure following MI
The move is based on the first indication-seeking registry-based randomised controlled trial
UK animal research dips 3.4% in 2019
Animal testing has dipped to its lowest figure since 2007, but Animal Free Research UK has condemned the results as ‘yet another wasted opportunity’
NICE backing for Astella’s Xospata
The drug is considered a cost-effective treatment for relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia
PM to announce extra £3bn for NHS
The funds are to help the health service prepare for a winter wave of coronavirus
